McCrady C W, Li F, Pettit G R, Grant S
Department of Medicine, Medical College of Virginia, Richmond.
Exp Hematol. 1993 Jul;21(7):893-900.
We have examined the effect of the macrocyclic lactone protein kinase C (PK-C) activator bryostatin 1 on the proliferative capacity and lineage commitment of CD34+ human bone marrow cells exposed to the granulocyte-macrophage colony-stimulating factor/interleukin-3 (GM-CSF/IL-3) fusion protein pIXY 321. pIXY 321 administered at a dose of 10 ng/mL was as effective as the combination of plateau concentrations of recombinant (r) IL-3 and rGM-CSF (e.g., 50 ng/mL) in stimulating the growth of day-14 committed myeloid progenitors (colony-forming units granulocyte/macrophage [CFU-GM]). In the large majority of samples tested, coadministration of 0.5 to 100 nM bryostatin 1 with either pIXY 321 or the combination of rIL-3 plus rGM-CSF led to modest but significant increases (e.g., 30 to 75%) in the number of CFU-GM, compared to administration of growth factors alone. The degree of bryostatin 1-induced potentiation, however, was considerably less than that previously observed in the case of cells exposed to either rIL-3 or rGM-CSF, where increases of 100 to 150% were regularly noted. While at least 50% of day-14 CFU-GM stimulated by either pIXY 321 or the combination of rIL-3 plus rGM-CSF were of the pure or mixed eosinophilic variety, coadministration of bryostatin 1 resulted in a dramatic inhibition of eosinophilic colonies and a corresponding increase in pure and mixed neutrophil and macrophage colonies. Although coadministration of recombinant granulocyte colony-stimulating factor (rG-CSF) or recombinant colony-stimulating factor-1 (rCSF-1) mimicked the capacity of bryostatin 1 to increase the total number of pIXY 321-induced day-14 CFU-GM, these growth factors, unlike bryostatin 1, were not capable of inhibiting eosinophilic colony formation. Furthermore, whereas addition of neutralizing antibodies to G-CSF or CSF-1 blocked the capacity of these growth factors to potentiate colony formation in the presence of pIXY 321, it did not abrogate the effect of bryostatin 1 on progenitor cell growth or lineage commitment. Finally, in contrast to its effects on committed myeloid progenitors, bryostatin 1 did not increase the growth of erythroid (burst-forming units-erythroid [BFU-E]) and multipotent (multipotent colony-forming units [CFU-GEMM]) progenitors stimulated by pIXY 321, but instead inhibited colony formation at higher concentrations (e.g., 10 to 100 nM).(ABSTRACT TRUNCATED AT 400 WORDS)
我们研究了大环内酯类蛋白激酶C(PK-C)激活剂苔藓抑素1对暴露于粒细胞-巨噬细胞集落刺激因子/白细胞介素-3(GM-CSF/IL-3)融合蛋白pIXY 321的CD34+人骨髓细胞增殖能力和谱系定向的影响。以10 ng/mL的剂量给予pIXY 321在刺激第14天定向髓系祖细胞(集落形成单位粒细胞/巨噬细胞[CFU-GM])生长方面与重组(r)IL-3和rGM-CSF的平台浓度组合(如50 ng/mL)一样有效。在大多数测试样本中,与单独给予生长因子相比,0.5至100 nM苔藓抑素1与pIXY 321或rIL-3加rGM-CSF组合共同给药导致CFU-GM数量适度但显著增加(如30%至75%)。然而,苔藓抑素1诱导的增强程度远低于先前在暴露于rIL-3或rGM-CSF的细胞中观察到的程度,在后者中经常注意到增加100%至150%。虽然由pIXY 321或rIL-3加rGM-CSF组合刺激的第14天CFU-GM中至少50%是纯嗜酸性或混合嗜酸性类型,但苔藓抑素1共同给药导致嗜酸性集落显著抑制,以及纯中性粒细胞和巨噬细胞集落及混合集落相应增加。虽然重组粒细胞集落刺激因子(rG-CSF)或重组集落刺激因子-1(rCSF-1)共同给药模拟了苔藓抑素1增加pIXY 321诱导的第14天CFU-GM总数的能力,但这些生长因子与苔藓抑素1不同,不能抑制嗜酸性集落形成。此外,虽然添加针对G-CSF或CSF-1的中和抗体在存在pIXY 32时阻断了这些生长因子增强集落形成的能力,但它并未消除苔藓抑素1对祖细胞生长或谱系定向的影响。最后,与它对定向髓系祖细胞的作用相反,苔藓抑素1并未增加pIXY 321刺激的红系祖细胞(爆式红系集落形成单位[BFU-E])和多能祖细胞(多能集落形成单位[CFU-GEMM])的生长,反而在较高浓度(如10至100 nM)下抑制集落形成。(摘要截断于400字)